Key result
Aliskiren/amlodipine combination therapy provided a more effective systolic blood pressure reduction than aliskiren monotherapy or amlodipine monotherapy without increasing adverse events.
Why the study?
Does combination therapy with aliskiren and amlodipine improve blood pressure reduction compared to monotherapy in adults with essential hypertension?
Meta-Analysis (n=6,074)
Does combination therapy with aliskiren and amlodipine improve blood pressure reduction compared to monotherapy in adults with essential hypertension?
Combination therapy with aliskiren and amlodipine provides superior blood pressure reduction compared to either drug alone without increasing overall adverse events, and may reduce amlodipine-induced peripheral edema.
Answers are grounded in this paper and cite their sources.
Supports aliskiren/amlodipine combination in essential hypertension; extends Level-1 evidence beyond individual trials.
BACKGROUND: Aliskiren is a novel renin-angiotensin aldosterone system (RAAS) inhibitor, the combination therapy of aliskiren and amlodipine for blood pressure control have been reported recently. The primary objective of this analysis is to review recently reported randomized controlled trials (RCTs) to compare antihypertensive effects and adverse events between mono (amlodipine or aliskiren alone) and combination therapy of both medicines. METHODS: Databases for the search included Pubmed, Embase and the Cochrane Central Register of Controlled Trials. Revman v5.0 statistical program was used to analyze the data. Weighted mean differences (WMD) with a 95% confidence interval (CI) were used for the calculation of continuous data, and relative risk (RR) with a 95% CI was used for dichotomous data. RESULTS: We analyzed the data from 7 RCTs for a total of 6074 participants in this meta-analysis. We found that the aliskiren/amlodipine combination therapy had a stronger effect in lowering blood pressure as compared with the monotherapy using aliskiren (SBP: WMD = -10.42, 95% CI -13.03∼-7.82, P<0.00001; DBP: WMD = -6.60, 95% CI -7.22∼-5.97, P<0.00001) or amlodipine (SBP: WMD = -4.85, 95% CI -6.88∼-2.81, P<0.00001; DBP: WMD = -2.91, 95% CI -3.85∼-1.97, P<0.00001). No differences were found in terms of adverse events between combination therapy and monotherapy, except for the rates of peripheral edema and hypokalaemia which were significantly lower in the combination therapy than in the amlodipine monotherapy (RR = 0.78, 0.66∼0.92, P = 0.004; RR = 0.51, 0.27∼0.97, P = 0.04). Similar antihypertensive effects were found in both obese (body mass index > = 30 kg/m(2)) hypertensive and non-obese (body mass index <30 kg/m(2)) hypertensive patients. Moreover, there was no difference with the blood pressure lowering or adverse effects with regards to the combination therapy in both subgroups. CONCLUSION: We found that aliskiren/amlodipine combination therapy provided a more effective blood pressure reduction than monotherapy with either drug without increase in the occurrence of adverse events.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2013) conducted a meta-analysis in Essential Hypertension (n=6,074). Aliskiren and amlodipine combination therapy vs. Aliskiren or amlodipine monotherapy was evaluated on Systolic blood pressure reduction (combination vs aliskiren monotherapy) (WMD -10.42, 95% CI -13.03 to -7.82, p=<0.00001). Aliskiren/amlodipine combination therapy provided a more effective systolic blood pressure reduction than aliskiren monotherapy or amlodipine monotherapy without increasing adverse events.
Synapse has enriched 10 related papers. Consider them for comparative context: